Outcomes Associated with Apixaban Use in End-Stage Kidney Disease Patients with Atrial Fibrillation in the United States.
Conclusions -Among ESKD patients with AF on dialysis, apixaban use may be associated with lower risk of major bleeding compared with warfarin, with a standard 5 mg twice a day dose also associated with reductions in thromboembolic and mortality risk.
PMID: 29954737 [PubMed - as supplied by publisher]
Source: Circulation - Category: Cardiology Authors: Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, Tilea A, Stack AG, Balkrishnan R, Yao X, Noseworthy PA, Shah ND, Saran R, Nallamothu BK Tags: Circulation Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Clinical Trials | Coumadin | Dialysis | Gastroenterology | Medicare | Pradaxa | Stroke | Study | Urology & Nephrology | USA Health | Warfarin | Women